Evidence map›Paper›PMID 28667212›Full record

SynthesisBMJ open2017

Seroprevalence of hepatitis B virus infection in Cameroon: a systematic review and meta-analysis.

Jean Joel Bigna, Marie A Amougou, Serra Lem Asangbeh, Angeladine Malaha Kenne, Steve Raoul N Noumegni, Elodie T Ngo-Malabo, Jean Jacques Noubiap

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMJ open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 22 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 22 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 22 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jean Joel BignaDepartment of Epidemiology and Public Health, Centre Pasteur of Cameroon, Yaoundé, Cameroon.ORCID 0000-0001-8018-6279
Marie A AmougouDepartment of Virology, Centre Pasteur of Cameroon, Yaoundé, Cameroon.
Serra Lem AsangbehAgence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS), Yaoundé, Cameroon.
Angeladine Malaha KenneDepartment of Epidemiology and Public Health, Centre Pasteur of Cameroon, Yaoundé, Cameroon.
Steve Raoul N NoumegniSchool of Public Health, Faculty of Medicine, University of Paris Sud XI, Le Kremlin Bicêtre, France.
Elodie T Ngo-MalaboDepartment of Virology, Centre Pasteur of Cameroon, Yaoundé, Cameroon.
Jean Jacques NoubiapDepartment of Medicine, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveBetter knowledge of hepatitis B virus (HBV) infection prevalence at the national level can help to implement pertinent strategies to address HBV related burden. The aim was to estimate the seroprevalence of HBV infection in Cameroon.

designSystematic review and meta-analysis.

participantsPeople residing in Cameroon. DATA SOURCES: Electronic databases including PubMed/MEDLINE, African Journals Online (AJOL), ScienceDirect, WHO-Afro Library, WHO-IRIS, African Index Medicus, National Institute of Statistics and National AIDS Control Committee, Cameroon; regardless of language and from 1 January 2000 to 30 September 2016. This was completed with a manual search of references of relevant papers. Risk of bias in methodology of studies was measured using the Newcastle-Ottawa Scale.

resultsOut of 511 retrieved papers, 44 studies with a total of 105 603 individuals were finally included. The overall pooled seroprevalence was 11.2% (95% CI 9.7% to 12.8%) with high heterogeneity between studies ( LIMITATION: Only a third of the studies had low risk of bias in their methodology.

conclusionThe seroprevalence of HBV infection in Cameroon is high. Effective strategies to interrupt the transmission of HBV are urgently required. Specific attention is needed for rural settings, certain regions and people born before the implementation of the HBV universal immunisation programme in Cameroon in 2005. REGISTRATION: PROSPERO, CRD42016042654.

Indexed as

CameroonCase-Control StudiesCohort StudiesCost of IllnessCross-Sectional StudiesDeveloping CountriesFemaleHepatitis BHumansMalePrevalenceRisk FactorsRural PopulationSeroepidemiologic StudiesAfricaCameroonHBVhepatitis Bhepatitis B virusPrevalence

Identifiers

PMID28667212
PMCPMC5734365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.